These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36505756)

  • 1. Elevated Serum Levels of CCL23 Are Associated with Poor Outcome after Resection of Biliary Tract Cancer.
    Roderburg C; Labuhn S; Bednarsch J; Lang SA; Schneider AT; Hammerich L; Vucur M; Ulmer TF; Neumann UP; Luedde T; Loosen SH
    Mediators Inflamm; 2022; 2022():6195004. PubMed ID: 36505756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
    Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
    JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Levels of CXCL13 Are an Independent Predictor of Survival Following Resection of Biliary Tract Cancer.
    Loosen SH; Ulmer TF; Labuhn S; Bednarsch J; Lang SA; Alizai PH; Schneider AT; Vucur M; Neumann UP; Luedde T; Roderburg C
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golgi Protein 73 (GP73) Serum Levels Predict Outcome after Resection of Biliary Tract Cancer.
    Loosen SH; Halpaap J; Labuhn S; Bednarsch J; Alizai PH; Roeth AA; Lang SA; Vucur M; Kather JN; Knoefel WT; Ulmer TF; Neumann UP; Roderburg C; Luedde T
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma.
    Roderburg C; Loosen SH; Bednarsch J; Alizai PH; Roeth AA; Schmitz SM; Vucur M; Luedde M; Paffenholz P; Tacke F; Trautwein C; Ulmer TF; Neumann UP; Luedde T
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bioinformatics analysis and significance of expression of CC chemokine ligand 23 (CCL23) in hepatocellular carcinoma].
    Lu J; Yang Y; Yu P; Tao H; Lu X; Wang L; Liu D; Chen Y; Chen C
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):903-909. PubMed ID: 31814567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.
    Sandanayake NS; Sinclair J; Andreola F; Chapman MH; Xue A; Webster GJ; Clarkson A; Gill A; Norton ID; Smith RC; Timms JF; Pereira SP
    Br J Cancer; 2011 Oct; 105(9):1370-8. PubMed ID: 21970875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
    Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
    Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer.
    Christensen TD; Maag E; Larsen O; Feltoft CL; Nielsen KR; Jensen LH; Leerhøy B; Hansen CP; Chen IM; Nielsen DL; Johansen JS
    JHEP Rep; 2023 Mar; 5(3):100648. PubMed ID: 36699667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.
    Yamashita S; Passot G; Aloia TA; Chun YS; Javle M; Lee JE; Vauthey JN; Conrad C
    Br J Surg; 2017 Feb; 104(3):267-277. PubMed ID: 28052308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of CC chemokine ligand 23 (CCL23)/ transcription factor activating enhancer binding protein 4 (TFAP4) on cell proliferation, invasion and angiogenesis in hepatocellular carcinoma.
    Wang W; Wu J; Dai X; Cheng K
    Bioengineered; 2022 Jan; 13(1):1626-1636. PubMed ID: 35001801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the large amino acid transporter SLC7A5/LAT1 on immune cells is enhanced in primary sclerosing cholangitis-associated cholangiocarcinoma and correlates with poor prognosis in cholangiocarcinoma.
    Branchi V; Hosni R; Kiwitz L; Ng S; van der Voort G; Bambi N; Kleinfelder E; Esser LK; Dold L; Langhans B; Gonzalez-Carmona MA; Ting S; Kristiansen G; Kalff JC; Thurley K; Hölzel M; Matthaei H; Toma MI
    Hum Pathol; 2024 Nov; 153():105670. PubMed ID: 39406289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery.
    Akazawa Y; Mizuno S; Fujinami N; Suzuki T; Yoshioka Y; Ochiya T; Nakamoto Y; Nakatsura T
    Sci Rep; 2019 Apr; 9(1):5925. PubMed ID: 30976046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Novel Biomarker for Biliary Tract Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.
    Kikkawa S; Sogawa K; Satoh M; Umemura H; Kodera Y; Matsushita K; Tomonaga T; Miyazaki M; Yokosuka O; Nomura F
    Int J Proteomics; 2012; 2012():108609. PubMed ID: 22888427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma.
    Zhou C; Zhou HJ; Zhang XF; Lou LL; Ye QH; Zheng Y; Wang J; Zhu HT; Dong QZ; Jia HL; Zhu WW; Guo L; Zhao Y; Gao DM; Qin LX
    Ann Surg Oncol; 2013 Mar; 20(3):929-37. PubMed ID: 23203407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.
    Motoyama H; Kobayashi A; Yokoyama T; Shimizu A; Kitagawa N; Notake T; Fukushima K; Masuo H; Yoshizawa T; Miyagawa SI
    World J Surg; 2017 Nov; 41(11):2817-2829. PubMed ID: 28717913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC.
    Loosen SH; Castoldi M; Jördens MS; Roy S; Vucur M; Kandler J; Hammerich L; Mohr R; Tacke F; Ulmer TF; Neumann UP; Luedde T; Roderburg C
    PLoS One; 2021; 16(3):e0247917. PubMed ID: 33711036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Preoperative Portal Vein Embolization Among Patients with Hepatocellular Carcinoma, Biliary Tract Cancer, and Colorectal Liver Metastases: A Comparative Study Based on Single-Center Experience of 319 Cases.
    Yamashita S; Sakamoto Y; Yamamoto S; Takemura N; Omichi K; Shinkawa H; Mori K; Kaneko J; Akamatsu N; Arita J; Hasegawa K; Kokudo N
    Ann Surg Oncol; 2017 Jun; 24(6):1557-1568. PubMed ID: 28188502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density as a prognostic marker in patients with biliary tract cancer undergoing surgery.
    Heinrichs L; Fluegen G; Loosen SH; Loberg C; Wittig L; Quaas A; Plum PS; Große Hokamp N; Minko P; Krieg A; Antoch G; Knoefel WT; Luedde T; Roderburg C; Jördens MS
    BJC Rep; 2024 Dec; 2(1):72. PubMed ID: 39323978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.